ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma
─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─
Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising cancer therapies, today announced that Cancer Focus Fund is investing $5 million in funding to support ISA103, ISA’s PRAME-targeting immunotherapy, in a first-in-human study for the treatment of uveal melanoma, a rare ocular cancer.
